Blinatumomab is a groundbreaking bispecific T-cell engager antibody construct that represents a novel class of immunotherapy for hematologic malignancies. Structurally, Blinatumomab is a recombinant bispecific single-chain antibody construct that simultaneously targets CD19, a surface antigen expressed on B cells, and CD3, a component of the T-cell receptor complex on T cells. By binding to both targets, Blinatumomab physically bridges cytotoxic T cells with CD19-positive target cells, forcing the formation of a cytolytic synapse that triggers T-cell activation, proliferation, and subsequent lysis of target cells regardless of T-cell receptor specificity.The successful development and clinical use of Blinatumomab depend on robust bioanalytical methods to support pharmacokinetic studies, immunogenicity assessments, and therapeutic monitoring. As a bispecific construct, Blinatumomab presents unique bioanalytical challenges compared to conventional monoclonal antibodies. Reliable quantification of Blinatumomab concentrations in biological matrices is essential for understanding the relationship between drug exposure and clinical response. Additionally, detection of anti-Blinatumomab antibodies is critical for evaluating immunogenicity, as treatment-emergent anti-drug antibodies can neutralize activity, alter pharmacokinetics, and potentially trigger adverse events.
Figure 1. Anti-Blinatumomab ELISA Kit for Immunogenicity Monitoring.
Bispecific T-cell engager constructs represent an innovative approach to cancer immunotherapy that differs fundamentally from conventional monoclonal antibodies. Rather than simply blocking a signaling pathway or marking cells for destruction by immune effector cells, bispecific T-cell engager constructs actively recruit and activate T cells to kill target cells. This mechanism harnesses the full cytotoxic potential of the patient's own T cells, which are present in large numbers even in patients with advanced cancer. Bispecific T-cell engager constructs are typically formatted as single-chain variable fragment molecules composed of two linked single-chain variable fragments: one directed against a tumor-associated antigen and one directed against CD3 on T cells. The small size of these constructs enables close contact between T cells and target cells, facilitating the formation of a functional cytolytic synapse. Following synapse formation, T cells become activated independent of their native T-cell receptor specificity, releasing perforin and granzymes that induce target cell apoptosis.
Blinatumomab is a bispecific T-cell engager construct that targets CD19 and CD3. CD19 is a transmembrane glycoprotein expressed on the surface of B cells from the early pre-B cell stage through mature B cells, making it an excellent target for B-cell malignancies. CD19 is expressed on the vast majority of B-cell acute lymphoblastic leukemia cells and is also present on normal B cells, which are eliminated as part of the therapeutic effect. Upon administration, Blinatumomab binds simultaneously to CD19 on malignant B cells and to CD3 on T cells. This binding physically links T cells to target cells, bringing them into close proximity. The engagement of CD3 triggers T-cell activation through signaling pathways that resemble those activated by the native T-cell receptor complex. Activated T cells upregulate activation markers, proliferate, and release cytotoxic granules that penetrate the target cell membrane, inducing apoptotic cell death.
Blinatumomab is approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in both adults and children. In pivotal clinical trials, Blinatumomab induced complete remissions in a substantial proportion of patients who had failed multiple prior lines of therapy, including many who had undergone allogeneic stem cell transplantation. The duration of response in some patients has been durable, suggesting that Blinatumomab may eliminate leukemia stem cells or induce lasting immune memory. The safety profile of Blinatumomab is distinct from conventional chemotherapy and from other immunotherapies. Cytokine release syndrome, characterized by fever, hypotension, and elevated inflammatory cytokines, is a common and potentially serious adverse event that requires careful monitoring and management. Neurologic events including seizure, encephalopathy, and confusion have also been observed. These toxicities are generally manageable with supportive care, dose interruption, or treatment discontinuation.
| Bioanalytical Considerations for Blinatumomab | Details |
| Unique Challenges of Bispecific Quantification | Quantification of Blinatumomab presents unique challenges compared to conventional monoclonal antibodies. The bispecific nature of the molecule means that functional activity depends on the ability to bind both CD19 and CD3 simultaneously. Assays that detect only one binding activity may not accurately reflect the concentration of fully functional bispecific construct. |
| Importance of Functional Activity Assessment | For pharmacokinetic characterization of Blinatumomab, measurement of functional bispecific activity is critical. The Free Anti-CD3/CD19 ELISA Kit is designed to detect Blinatumomab that retains the ability to bind both CD3 and CD19, representing the pharmacologically active species capable of bridging T cells and target cells. |
The Anti-Blinatumomab ELISA Kit is designed for the detection and semi-quantitative determination of anti-Blinatumomab antibodies in human serum, plasma, or other biological fluids. This kit is optimized for immunogenicity assessment in clinical research and regulatory-compliant environments.
The Free Anti-CD3/CD19 (Blinatumomab) ELISA Kit is designed for the quantitative determination of functional Blinatumomab concentrations in human serum, plasma, or other biological matrices. This kit is optimized for pharmacokinetic studies and therapeutic monitoring applications.
Blinatumomab represents a transformative therapy for B-cell acute lymphoblastic leukemia, harnessing the power of the patient's own T cells to eliminate malignant B cells through bispecific T-cell engager technology. Reliable bioanalytical methods are essential for supporting the clinical development and optimal use of this innovative therapeutic. The Anti-Blinatumomab ELISA Kit provides a validated, sensitive, and specific solution for detecting anti-Blinatumomab antibodies, supporting immunogenicity assessment that meets regulatory expectations. The Free Anti-CD3/CD19 (Blinatumomab) ELISA Kit enables accurate quantification of functional drug concentrations, facilitating pharmacokinetic characterization and therapeutic drug monitoring. Together, these kits provide a comprehensive bioanalytical toolkit for researchers and clinicians working with Blinatumomab across all stages of development and clinical use.
| Cat. No. | Product Name | Species Reactivity | Detection Method | |
| DEIA-JY25237 | Anti-Blinatumomab ELISA Kit | Human | sELISA | Inquiry |
| DEIA-JY25255 | Free Anti-CD3 / CD19 (Blinatumomab) ELISA Kit | Human | sELISA | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| CD3 | CABT-CS549 | Human Anti-Human CD3 & CD19 (Blinatumomab) Monoclonal antibody, clone Blinatumomab | Human | IgG1 | ELISA | Inquiry |
